Neuland Laboratories Limited

NSEI:NEULANDLAB Stock Report

Market Cap: ₹191.7b

Neuland Laboratories Valuation

Is NEULANDLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NEULANDLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NEULANDLAB (₹16068.9) is trading above our estimate of fair value (₹7354.42)

Significantly Below Fair Value: NEULANDLAB is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NEULANDLAB?

Key metric: As NEULANDLAB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NEULANDLAB. This is calculated by dividing NEULANDLAB's market cap by their current earnings.
What is NEULANDLAB's PE Ratio?
PE Ratio73.8x
Earnings₹2.80b
Market Cap₹191.72b

Price to Earnings Ratio vs Peers

How does NEULANDLAB's PE Ratio compare to its peers?

The above table shows the PE ratio for NEULANDLAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average83.5x
ERIS Eris Lifesciences
57.4x30.7%₹200.0b
506820 AstraZeneca Pharma India
198.3xn/a₹162.4b
MARKSANS Marksans Pharma
45.1x22.3%₹156.6b
APLLTD Alembic Pharmaceuticals
33.1x21.5%₹213.9b
NEULANDLAB Neuland Laboratories
73.8x33.9%₹206.4b

Price-To-Earnings vs Peers: NEULANDLAB is good value based on its Price-To-Earnings Ratio (73.8x) compared to the peer average (83.5x).

Price to Earnings Ratio vs Industry

How does NEULANDLAB's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.5xn/aUS$66.29m
524652 Ind-Swift
2.1xn/aUS$13.37m
No more companies available in this PE range
NEULANDLAB 73.8xIndustry Avg. 34.2xNo. of Companies17PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NEULANDLAB is expensive based on its Price-To-Earnings Ratio (73.8x) compared to the Indian Pharmaceuticals industry average (34.2x).

Price to Earnings Ratio vs Fair Ratio

What is NEULANDLAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NEULANDLAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio73.8x
Fair PE Ratio51.6x

Price-To-Earnings vs Fair Ratio: NEULANDLAB is expensive based on its Price-To-Earnings Ratio (73.8x) compared to the estimated Fair Price-To-Earnings Ratio (52.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NEULANDLAB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹16,068.90
₹17,625.00
+9.7%
13.5%₹20,000.00₹15,250.00n/a2
Nov ’25₹14,560.85
₹16,875.00
+15.9%
18.5%₹20,000.00₹13,750.00n/a2
Oct ’25₹12,508.25
₹12,337.50
-1.4%
5.2%₹12,975.00₹11,700.00n/a2
Sep ’25₹12,502.20
₹11,550.00
-7.6%
1.3%₹11,700.00₹11,400.00n/a2
Aug ’25₹9,381.55
₹9,450.00
+0.7%
20.6%₹11,400.00₹7,500.00n/a2
Jul ’25₹7,717.65
₹8,300.00
+7.5%
9.6%₹9,100.00₹7,500.00n/a2
Jun ’25₹6,042.50
₹8,300.00
+37.4%
9.6%₹9,100.00₹7,500.00n/a2
May ’25₹7,593.45
₹8,300.00
+9.3%
9.6%₹9,100.00₹7,500.00n/a2
Aug ’24₹3,487.50
₹2,505.00
-28.2%
37.7%₹3,450.00₹1,560.00₹9,381.552
Jul ’24₹2,830.75
₹2,505.00
-11.5%
37.7%₹3,450.00₹1,560.00₹7,717.652
Jun ’24₹2,737.30
₹2,280.00
-16.7%
31.6%₹3,000.00₹1,560.00₹6,042.502
May ’24₹2,139.15
₹1,830.00
-14.5%
14.8%₹2,100.00₹1,560.00₹7,593.452
Apr ’24₹1,804.05
₹1,830.00
+1.4%
14.8%₹2,100.00₹1,560.00₹6,265.852
Mar ’24₹1,581.60
₹1,830.00
+15.7%
14.8%₹2,100.00₹1,560.00₹7,268.502
Feb ’24₹1,434.80
₹1,786.00
+24.5%
17.6%₹2,100.00₹1,472.00₹6,242.652
Jan ’24₹1,666.95
₹1,786.00
+7.1%
17.6%₹2,100.00₹1,472.00₹5,282.552
Dec ’23₹1,734.95
₹1,664.67
-4.1%
18.5%₹2,100.00₹1,422.00₹5,370.653
Nov ’23₹1,485.75
₹1,420.00
-4.4%
21.9%₹1,800.00₹1,038.00₹3,857.053

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,197.45

7D

0.8%

1Y

-23.0%

Novartis India

₹26.1b

Operates as a healthcare company in India.

500672

₹1,058.30

7D

3.5%

1Y

52.4%